Overview

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sorrento Therapeutics, Inc.

Treatments:

Abivertinib